Home | | Psychiatry | Linking NMDA Receptors to Biogenic Amine-based Anxiolytics

Chapter: Essentials of Psychiatry: Psychiatric Pathophysiology: Anxiety Disorders

Linking NMDA Receptors to Biogenic Amine-based Anxiolytics

Linking NMDA Receptors to Biogenic Amine-based Anxiolytics
In preclinical studies, chronic treatment with biogenicamine– based antidepressants used in the treatment of anxiety disorders blunts NMDA receptor function.

Linking NMDA Receptors to Biogenic Amine-based Anxiolytics

 

In preclinical studies, chronic treatment with biogenicamine– based antidepressants used in the treatment of anxiety disorders blunts NMDA receptor function (Skolnick, 1999). In view of the anxiolytic-like actions of NMDA antagonists in preclinical tests, the body of evidence indicates that NMDA receptors may represent a downstream target for biogenic amine-based antidepressants. While this hypothesis has been used to explain the therapeutic lag associated with biogenic amine-based antidepressants (Skolnick, 1999), it may also contribute to the delay in onset of these serotonin and norepinephrine modulators used to treat anxiety disorders (Figure 12.4).


Study Material, Lecturing Notes, Assignment, Reference, Wiki description explanation, brief detail
Essentials of Psychiatry: Psychiatric Pathophysiology: Anxiety Disorders : Linking NMDA Receptors to Biogenic Amine-based Anxiolytics |


Privacy Policy, Terms and Conditions, DMCA Policy and Compliant

Copyright © 2018-2023 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.